MedTrace Logo

Efficacy of PJS-539 for Adult Patients With COVID-19.

NCT05008393 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2022-04-12

No results posted yet for this study

Summary

The PJS-539 is a multicentre, phase 2, randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of PJS-539 in the viral load of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Conditions

Interventions

DRUG

PJS-539 Dose 1

Patients will receive PJS-539 dose 1 daily for 10 days.

DRUG

PJS-539 Dose 2

Patients will receive PJS-539 Dose 2 daily for 10 days.

DRUG

Placebo

Patients will receive placebo daily for 10 days.

Sponsors & Collaborators

  • Covicept

    collaborator UNKNOWN

  • Hospital do Coracao

    lead OTHER

Principal Investigators

  • Bruno Tomazini, MD · Hospital do Coracao

  • Alexandre Biasi Cavalcanti, MD, PhD · Hospital do Coracao

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-25
Primary Completion
2022-02-03
Completion
2022-03-04

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05008393 on ClinicalTrials.gov